; (ii) the date of approval and application number for each such biological product; (iii) the marketing status, dosage form, route of administration, strength, and, if applicable, reference product, for each such biological product; (iv) the licensure status for each such biological product, including whether the license at the time of listing is approved, withdrawn, or revoked; (v) for each such biological product that is a reference product for which an exclusivity period applies, and for which the Secretary has determined the dates of such exclusivity period, under subsection (k)(7)(A) or subsection (k)(7)(B) of this section or under section 527 of the Federal Food, Drug, and Cosmetic Act, including any extension of such exclusivity period in accordance with subsection (m) of this section, the date on which such exclusivity period expires; (vi) any determination of biosimilarity or interchangeability for each such biological product; and (vii) information regarding approved indications for each such biological product, in such manner as the Secretary determines appropriate. (B) Updates Every 30 days after the publication of the first list under subparagraph (A), the Secretary shall revise the list to include— (i) (I) each biological product licensed under subsection (a) or (k) during the 30-day period; and (II) with respect to each biological product described in subclause (I), the information described in clauses (i) through (vii) of subparagraph (A)